Evaluation of urinary N-telopeptide of type i collagen measurements in the management of osteoporosis in clinical practice

Osteoporosis International

Volumn 24, Issue 3, 2013, Pages 941-947

  Baxter, I ^a   Rogers, A ^a   Eastell, R ^a,c   Peel, N ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Biochemical markers of bone turnover; Bisphosphonate; Dual energy X ray absorptiometry; Monitoring; Osteoporosis

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; DRUG RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT MONITORING; PREMENOPAUSE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN TYPE I; DIPHOSPHONATES; DRUG MONITORING; FEMALE; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PEPTIDES; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 84878885708     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-2097-4     Document Type: Article

References (18)

1. Eastell R (2003) Bone turnover markers: their place in the investigation of osteoporosis. In: Orwoll E, Bliziotes M (eds) Oteoporosis. Pathophysiology and clinical management. Contemporary endocrinology. Humana, Totowa, pp 185-197
2. Seibel MJ (2006) Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis. Clin Biochem Rev 27:123-138
3. Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89(3):1117-1123
4. Braga de Castro Machado A, Hannon R, Hannon R, Eastell R (1999) Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 14(4):602-608. doi: 10.1359/jbmr.1999.14.4.602
5. Rogers A, Glover SJ, Eastell R (2009) A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. Bone 45(6):1044-1052. doi: 10.1016/j.bone.2009. 07.089
6. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 11:2-17
7. Henriksen DB, Alexandersen P, Bjarnason NH, Vilsboll T, Hartmann B, Henriksen EE, Byrjalsen I, Krarup T, Holst JJ, Christiansen C (2003) Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 18(12):2180-2189. doi: 10.1359/jbmr.2003.18.12.2180
8. Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R (2008) Establishing a reference range for bone turnover markers in young, healthy women. Bone 42(4):623-630. doi: 10.1016/j.bone.2007.12.218
9. Kelman A, Lane NE (2005) The management of secondary osteoporosis. Best Pract Res Clin Rheumatol 19(6):1021-1037. doi: 10.1016/j.berh.2005.06.005
10. Kaufman JM, Goemaere S (2008) Osteoporosis in men. Best Pract Res Clin Rheumatol 22(5):787-812. doi: 10.1016/j.beem.2008.09.005
11. Kok C, Sambrook PN (2009) Secondary osteoporosis in patients with an osteoporotic fracture. Best Pract Res Clin Rheumatol 23(6):769-779. doi: 10.1016/j.berh.2009.09.006
12. Clowes JA, Peel NFA, Blumsohn A, Gossiel E, Eastell R (2004) Can multiple measurements or pooled measurements reduce within subject variability? J Bone Miner Res 19(10):S375-S375
13. Patel R, Blake GM, Rymer J, Fogelman I (2000) Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women. Osteoporos Int 1:68-75
14. Sebba AI, Bonnick SL, Kagan R, Thompson DE, Skalky CS, Chen E, de Papp AE, Fosamax Actonel Comparison Trial i (2004) Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin 20(12):2031-2041
15. Eekman DA, Bultink IEM, Heijboer AC, Dijkmans BAC, Lems WF (2011) Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice. BMC Musculoskelet Disord 12:167. doi: 10.1186/1471-2474-12-167
16. Greenspan SL, Beck TJ, Resnick NM, Bhattacharya R, Parker RA (2005) Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. J Bone Miner Res 20(9):1525-1532. doi: 10.1359/JBMR.050508
17. Lewiecki EM (2010) Management of skeletal health in patients with asymptomatic primary hyperparathyroidism. J Clin Densitom 13(4):324-334. doi: 10.1016/j.jocd.2010.06.004
18. Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA (2004) Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89(7):3319-3325. doi: 10.1210/jc.2003-030908